Suppr超能文献

人类癌症突变的生物学机制和临床意义。

Biological Mechanisms and Clinical Significance of Mutations in Human Cancer.

机构信息

University of Hawai'i Cancer Center, Honolulu, Hawai'i.

Bascom Palmer Eye Institute, Sylvester Comprehensive Cancer Center, and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, Florida.

出版信息

Cancer Discov. 2020 Aug;10(8):1103-1120. doi: 10.1158/2159-8290.CD-19-1220. Epub 2020 Jul 20.

Abstract

Among more than 200 -mutant families affected by the "BAP1 cancer syndrome," nearly all individuals inheriting a mutant allele developed one or more malignancies during their lifetime, mostly uveal and cutaneous melanoma, mesothelioma, and clear-cell renal cell carcinoma. These cancer types are also those that, when they occur sporadically, are more likely to carry somatic biallelic mutations. Mechanistic studies revealed that the tumor suppressor function of BAP1 is linked to its dual activity in the nucleus, where it is implicated in a variety of processes including DNA repair and transcription, and in the cytoplasm, where it regulates cell death and mitochondrial metabolism. BAP1 activity in tumor suppression is cell type- and context-dependent. BAP1 has emerged as a critical tumor suppressor across multiple cancer types, predisposing to tumor development when mutated in the germline as well as somatically. Moreover, has emerged as a key regulator of gene-environment interaction..

摘要

在受“BAP1 癌症综合征”影响的 200 多个-突变家族中,几乎所有遗传突变等位基因的个体在其一生中都会发展出一种或多种恶性肿瘤,主要是葡萄膜和皮肤黑色素瘤、间皮瘤和肾透明细胞癌。这些癌症类型也是那些在偶发情况下更可能携带体双等位基因突变的癌症类型。机制研究表明,BAP1 的肿瘤抑制功能与其在核内的双重活性有关,在核内,它参与包括 DNA 修复和转录在内的多种过程,在细胞质内,它调节细胞死亡和线粒体代谢。BAP1 在肿瘤抑制中的活性取决于细胞类型和背景。BAP1 已成为多种癌症类型的关键肿瘤抑制因子,当在种系中发生突变以及在体细胞中发生突变时,都会导致肿瘤的发展。此外,它已成为基因-环境相互作用的关键调节剂。

相似文献

1
Biological Mechanisms and Clinical Significance of Mutations in Human Cancer.
Cancer Discov. 2020 Aug;10(8):1103-1120. doi: 10.1158/2159-8290.CD-19-1220. Epub 2020 Jul 20.
2
BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
Klin Onkol. 2019 Summer;32(Supplementum2):118-122. doi: 10.14735/amko2019S118.
3
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.
J Transl Med. 2012 Aug 30;10:179. doi: 10.1186/1479-5876-10-179.
5
Tumours associated with BAP1 mutations.
Pathology. 2013 Feb;45(2):116-26. doi: 10.1097/PAT.0b013e32835d0efb.
6
Germline BAP1 mutations predispose to malignant mesothelioma.
Nat Genet. 2011 Aug 28;43(10):1022-5. doi: 10.1038/ng.912.
7
A population-based analysis of germline BAP1 mutations in melanoma.
Hum Mol Genet. 2017 Feb 15;26(4):717-728. doi: 10.1093/hmg/ddw403.
9
Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations.
JAMA Ophthalmol. 2015 Aug;133(8):881-7. doi: 10.1001/jamaophthalmol.2015.1119.
10
Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients.
Ophthalmic Genet. 2015 Jun;36(2):126-31. doi: 10.3109/13816810.2015.1010734. Epub 2015 Feb 17.

引用本文的文献

1
Spontaneous Mesotheliomas in Germline Heterozygous Mice from Different Genetic Backgrounds.
Cancers (Basel). 2025 Aug 19;17(16):2692. doi: 10.3390/cancers17162692.
2
Ferroptosis as a therapeutic target in glioblastoma: Mechanisms and emerging strategies.
Mol Ther Nucleic Acids. 2025 Jul 30;36(3):102649. doi: 10.1016/j.omtn.2025.102649. eCollection 2025 Sep 9.
3
Pleural mesothelioma.
Nat Rev Dis Primers. 2025 Aug 7;11(1):56. doi: 10.1038/s41572-025-00640-3.
4
BAP1 complexes with YY1 and RBBP7 and its downstream targets in ccRCC cells.
Open Life Sci. 2025 Jul 18;20(1):20251140. doi: 10.1515/biol-2025-1140. eCollection 2025.
5
Early Genetic Evolution of Driver Mutations in Uveal Melanoma.
medRxiv. 2025 Jun 12:2025.06.10.25329358. doi: 10.1101/2025.06.10.25329358.
7
Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities.
Diagnostics (Basel). 2025 May 24;15(11):1323. doi: 10.3390/diagnostics15111323.
8
9
Novel anoikis-related genes for the diagnosis of non-obstructive azoospermia.
Transl Androl Urol. 2025 Apr 30;14(4):940-952. doi: 10.21037/tau-2024-745. Epub 2025 Apr 27.

本文引用的文献

2
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S100-S119. doi: 10.21037/tlcr.2019.11.23.
3
Chromosomal rearrangements and their neoantigenic potential in mesothelioma.
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S92-S99. doi: 10.21037/tlcr.2019.11.12.
4
5
Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma.
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S77-S85. doi: 10.21037/tlcr.2020.01.16.
6
Mesothelioma developing in carriers of inherited genetic mutations.
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S67-S76. doi: 10.21037/tlcr.2019.11.15.
7
BAP1: role in carcinogenesis and clinical implications.
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S60-S66. doi: 10.21037/tlcr.2019.11.24.
8
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S3-S27. doi: 10.21037/tlcr.2019.11.29.
10
Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations.
Endocr Pathol. 2019 Dec;30(4):276-284. doi: 10.1007/s12022-019-09595-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验